SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Immunomedics (IMMU) - moderated
An SI Board Since September 2006
Posts SubjectMarks Bans Symbol
63378 356 15 IMMU
Emcee:  idahoranch1 Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
61918error on my part for the 55% quote....it was that 55% of those ON blood thinnersscorman117/7/2023
61917Jargon, I particularly agree with your last paragraph, although there’s a case tOlecranon37/7/2023
61916For those who are invested in or follow AADI, are you aware of any change in funOlecranon-7/7/2023
61915Biogen down $10 on a real full approval....quite diff from the $20bill spike froscorman1-7/7/2023
61914Not sure that anyone outside of the FDA itself knows for sure what it is thinkinjargonweary57/7/2023
61913In our randomized withdrawal study that followed a 12-month open-label safety sterippetoe17/7/2023
61912SAVA...this about that: Biogen may have gotten approval, but they only expect 10scorman147/6/2023
61911From the NY Times: Still, some Alzheimer’s experts have said it is unclear froOlecranon27/6/2023
61910SAVA: too little, too late? cnn.com This is my daughter's first stock holdjhcimmu-7/6/2023
61909And this is the typical, torturous path that most small cap biotechs seem to takjargonweary47/5/2023
61908The data seems to indicate that Simufilam does slow AD decline but definitely wojargonweary57/5/2023
61907SAVA: Oral Simufilam Slowed Cognitive Decline in a Randomized Withdrawal Trial erickerickson17/5/2023
61906SRPT: Sarepta Therapeutics Announces Sale of Priority Review Voucher for $102 merickerickson-7/5/2023
61905Hmmm. TMF agrees with you: Why Shares of CymaBay Therapeutics Are Soaring Fridaerickerickson47/1/2023
61904Another Simufilam testimonial from an investor on Joe Springer's Discord whoghettogoulash16/30/2023
61903Apparently, their competitor $GNFT didn't do so well. twitter.comchandler27-6/30/2023
61902CBAY: OK, I understand AUPH spiking, currently up 11%+ with the announcement therickerickson-6/30/2023
61901Oops. Dilution was 2 million shares. ($1.4 million % $ .71 share price)ghettogoulash-6/29/2023
61900I'd take $17.50 a share and consider myself LUCKY !!!!!!!!!!!!!! Anything CLplhky3465-6/29/2023
61899AUPH explores strategic options (FINALLY!) AUPH RELEASEDavidoff56/29/2023
61898SRPT: I'm back in. I ended up selling 60% of my position at $153, because I ghettogoulash-6/29/2023
61897At the time, I also felt like H&J might just stick around anyway. I said: &ghettogoulash-6/29/2023
61896DBGI Analysis. I'm only posting this because a few here have expressed interghettogoulash-6/29/2023
61895This is from Alex at YMB, a synthetic chemist PhD who has worked in drug developghettogoulash16/28/2023
61894I guess it could just be that the unrealistic intentions of all parties were thwghettogoulash-6/28/2023
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News